RxDoctor Payments Data

Taylor Keen, PA

Family Medicine · Carlisle, PANPI 1215589056

Payments from drug & device makers

$9,790in general payments, 2019–2025

Across 508 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Bristol Myers Squibb$840
  • EMD Serono, Inc.$617
  • Biogen$583
  • Novartis$433
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$9,68699%
  • Education$1041%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,790 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$49,323
Medicare patients
281
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$214,191
Kesimpta PenOfatumumab11$103,775
QuliptaAtogepant36$63,356
RytaryCarbidopa/Levodopa51$56,801
Nurtec OdtRimegepant Sulfate19$48,982
AptiomEslicarbazepine Acetate20$34,111
BotoxOnabotulinumtoxina14$16,789
Emgality PenGalcanezumab-Gnlm11$11,156
Aimovig AutoinjectorErenumab-Aooe11$9,774
TrintellixVortioxetine Hydrobromide12$5,778
Carbidopa-Levodopa ErCarbidopa/Levodopa25$4,538
Rasagiline Mesylate27$4,127
Carbidopa-LevodopaCarbidopa/Levodopa142$3,883
Duloxetine Hcl95$3,210
Gabapentin123$2,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$262$214,19117 claims
AbbVieQulipta, Botox$1,390$80,14550 claims
Amneal Pharmaceuticals LLCRytary$273$56,80151 claims
PfizerNurtec Odt$125$48,98219 claims
Sunovion Pharmaceuticals Inc.Aptiom$16$34,11120 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$103$5,77812 claims
Upsher-smith Laboratories LLCTopiramate$33$16514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Carlisle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →